Jelmyto: Technology that reaches beyond the tumor

  • Using an innovative reverse-thermal hydrogel (RTGel™) that fills and conforms to the complex renal anatomy, Jelmyto allows for 4-6 hours of sustained exposure to mitomycin1
  • By delivering chemoablative therapy to the upper tract, Jelmyto completes the primary treatment regimen across diverse presentations, even those that are endoscopically unreachable1,2
Low-Volume/
Unifocal Disease
Higher-Volume/
Multifocal Disease
Unresectable
Tumor(s)
Jelmyto should NOT be instilled immediately following resection or ablation.
Kidney illustration with circled tumor

Multimodal Regimen:

  • Resection or ablation of visible disease3
  • Chemoablation with Jelmyto once weekly for 6 weeks for sustained exposure to mitomycin1
Kidney illustration with circled tumors
Kidney illustration with circled tumor

Featured resources

Download these resources to learn more and to get your appropriate patients started on Jelmyto treatment.

Jelmyto Brand Story Leave Behind

Download iconDownload

Jelmyto Nephrostomy Instructions

Download iconDownload

Scheduling and Ordering Resource

Download iconDownload

Program Overview Brochure

Download iconDownload

Jelmyto Patient Enrollment Form

Download iconDownload

Multimodal treatment algorithm

Assess which regimen is right for your patient with low-grade UTUC

Download now

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to UroGen Pharma at 1-855-987-6436.

Please click here for JELMYTO Full Prescribing Information, including the Patient Information, for additional information.

Please click here for Full Prescribing Information, Instructions for Pharmacy, and Instructions for Administration.